Theranexus (EPA:ALTHX) | WebDisclosure

PRESS RELEASE

published on 10/17/2024 at 18:00, 2 years ago

THERANEXUS S'ASSOCIE À SYNERLAB POUR PRÉPARER LA COMMERCIALISATION DE SA FORMULATION PÉDIATRIQUE DANS LA MALADIE DE NIEMANN-PICK DE TYPE C
Theranexus et Synerlab annoncent un partenariat pour la production du traitement Mig-OS pour la maladie de Niemann-Pick de type C. Lancement commercial prévu dès 2026

Theranexus EMA Synerlab Mig-OS Maladie De Niemann-Pick De Type C
PRESS RELEASE

published on 10/17/2024 at 18:00, 2 years ago

THERANEXUS JOINS UP WITH SYNERLAB TO PREPARE THE COMMERCIALIZATION OF ITS PEDIATRIC FORMULATION IN NIEMANN-PICK TYPE C DISEASE
Theranexus partners with Synerlab to produce oral solution of miglustat for Niemann-Pick type C disease, aiming for EMA approval and commercialization by 2026. Novel pediatric formulation Mig-OS provides new therapeutic option for NPC patients

Theranexus Synerlab Miglustat Niemann-Pick Type C Disease EMA Approval
BRIEF

published on 09/26/2024 at 18:05, 2 years 1 month ago

Theranexus annonce ses résultats financiers du premier semestre 2024

Résultats Financiers Biopharmaceutique Réduction Des Coûts Theranexus Batten-1
BRIEF

published on 09/26/2024 at 18:05, 2 years 1 month ago

Theranexus announces its financial results for the first half of 2024

Financial Results Cost Reduction Biopharmaceutical Theranexus Batten-1
PRESS RELEASE

published on 09/26/2024 at 18:00, 2 years 1 month ago

THERANEXUS ANNONCE SES RÉSULTATS FINANCIERS DU PREMIER SEMESTRE 2024
Theranexus, société biopharmaceutique, annonce ses résultats semestriels 2024. Baisse significative des charges d'exploitation grâce à la fin d'essais cliniques et efforts de réduction des coûts

Résultats Semestriels Biopharmaceutique Réduction Des Coûts Theranexus Maladies Neurologiques
PRESS RELEASE

published on 09/26/2024 at 18:00, 2 years 1 month ago

THERANEXUS ANNOUNCES FIRST HALF 2024 FINANCIAL RESULTS
Theranexus reports cost reduction success and positive first half 2024 financial results, led by completion of Batten-1 clinical trial and operating grants

Financial Results Cost Reduction Clinical Trial Theranexus Batten-1
BRIEF

published on 07/11/2024 at 18:50, 2 years 4 months ago

Theranexus annonce sa trésorerie au 30 juin 2024 et détaille le progrès de Batten-1

Financement Trésorerie Theranexus Batten-1 Maladie Neurologique
BRIEF

published on 07/11/2024 at 18:50, 2 years 4 months ago

Theranexus announces its cash flow as of June 30, 2024 and details the progress of Batten-1

Treasury Funding Theranexus Batten-1 Neurological Disease
PRESS RELEASE

published on 07/11/2024 at 18:45, 2 years 4 months ago

Theranexus publie sa trésorerie au 30 juin 2024 et fait le point sur l'avancement de Batten-1
Theranexus publie sa trésorerie au 30 juin 2024, avance sur Batten-1 et ouvre nouvelle ligne de financement en fonds propres. Commercialisation phase 3 Batten-1 en vue

Financement Trésorerie Fonds Propres Theranexus Batten-1
PRESS RELEASE

published on 07/11/2024 at 18:45, 2 years 4 months ago

Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1
Biopharmaceutical company Theranexus announces implementation of new equity line to finance Phase III trial for Batten-1 drug in juvenile Batten disease. Update on Batten-1 program included

Biopharmaceutical Company Phase III Trial Theranexus Batten-1 Equity Line

Published on 11/11/2026 at 22:30, 17 minutes ago

55 North Gold Qualifies for Trading on the OTCQB Venture Market and Launches New Corporate Website
Published on 11/11/2026 at 19:31, 3 hours 16 minutes ago

Lion Copper Corp. Completes S-K 1300 Technical Report Summary for Bear Copper Deposit
Published on 11/11/2026 at 16:30, 6 hours 17 minutes ago

ShelfieTech Announces Expansion Agreement for Its Next-Generation AI Retail Intelligence Platform
Published on 11/11/2026 at 14:25, 8 hours 22 minutes ago

Route1 Announces 2026 Annual Meeting Results
Published on 11/11/2026 at 14:00, 8 hours 47 minutes ago

PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026

View all ACCESSWIRE

Published on 11/11/2026 at 19:29, 3 hours 17 minutes ago

EQS-Adhoc: Allianz SE: Allianz delivers record nine-month result of 14.1 billion euros and raises 2026 outlook
Published on 11/11/2026 at 18:41, 4 hours 5 minutes ago

AUSTRIACARD HOLDINGS AG: 9M 2026 Financial Results
Published on 11/11/2026 at 18:37, 4 hours 9 minutes ago

Holding(s) in Company
Published on 11/11/2026 at 18:36, 4 hours 10 minutes ago

Holding(s) in Company
Published on 11/11/2026 at 18:35, 4 hours 11 minutes ago

Holding(s) in Company

View all EQS

Published on 11/10/2026 at 18:00, 1 day 4 hours ago

Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day 5 hours ago

Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:40, 1 day 5 hours ago

Production du 3ième trimestre 2026
Published on 11/10/2026 at 17:35, 1 day 5 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 5 hours ago

CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.

View all LES ECHOS COMFI WIRE

News